148 related articles for article (PubMed ID: 26365326)
1. Menopausal estrogen therapy and non-Hodgkin's lymphoma: A post-hoc analysis of women's health initiative randomized clinical trial.
Kato I; Chlebowski RT; Hou L; Wactawski-Wende J; Ray RM; Abrams J; Bock C; Desai P; Simon MS
Int J Cancer; 2016 Feb; 138(3):604-11. PubMed ID: 26365326
[TBL] [Abstract][Full Text] [Related]
2. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.
Shumaker SA; Legault C; Kuller L; Rapp SR; Thal L; Lane DS; Fillit H; Stefanick ML; Hendrix SL; Lewis CE; Masaki K; Coker LH;
JAMA; 2004 Jun; 291(24):2947-58. PubMed ID: 15213206
[TBL] [Abstract][Full Text] [Related]
3. Effects of oral conjugated equine estrogens with or without medroxyprogesterone acetate on incident hypertension in the Women's Health Initiative hormone therapy trials.
Swica Y; Warren MP; Manson JE; Aragaki AK; Bassuk SS; Shimbo D; Kaunitz A; Rossouw J; Stefanick ML; Womack CR
Menopause; 2018 Jul; 25(7):753-761. PubMed ID: 29381666
[TBL] [Abstract][Full Text] [Related]
4. Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials.
Chlebowski RT; Anderson GL; Aragaki AK; Manson JE; Stefanick ML; Pan K; Barrington W; Kuller LH; Simon MS; Lane D; Johnson KC; Rohan TE; Gass MLS; Cauley JA; Paskett ED; Sattari M; Prentice RL
JAMA; 2020 Jul; 324(4):369-380. PubMed ID: 32721007
[TBL] [Abstract][Full Text] [Related]
5. Effects of estrogen with and without progestin on urinary incontinence.
Hendrix SL; Cochrane BB; Nygaard IE; Handa VL; Barnabei VM; Iglesia C; Aragaki A; Naughton MJ; Wallace RB; McNeeley SG
JAMA; 2005 Feb; 293(8):935-48. PubMed ID: 15728164
[TBL] [Abstract][Full Text] [Related]
6. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.
Manson JE; Chlebowski RT; Stefanick ML; Aragaki AK; Rossouw JE; Prentice RL; Anderson G; Howard BV; Thomson CA; LaCroix AZ; Wactawski-Wende J; Jackson RD; Limacher M; Margolis KL; Wassertheil-Smoller S; Beresford SA; Cauley JA; Eaton CB; Gass M; Hsia J; Johnson KC; Kooperberg C; Kuller LH; Lewis CE; Liu S; Martin LW; Ockene JK; O'Sullivan MJ; Powell LH; Simon MS; Van Horn L; Vitolins MZ; Wallace RB
JAMA; 2013 Oct; 310(13):1353-68. PubMed ID: 24084921
[TBL] [Abstract][Full Text] [Related]
7. Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials.
Chlebowski RT; Rohan TE; Manson JE; Aragaki AK; Kaunitz A; Stefanick ML; Simon MS; Johnson KC; Wactawski-Wende J; O'Sullivan MJ; Adams-Campbell LL; Nassir R; Lessin LS; Prentice RL
JAMA Oncol; 2015 Jun; 1(3):296-305. PubMed ID: 26181174
[TBL] [Abstract][Full Text] [Related]
8. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials.
Manson JE; Aragaki AK; Rossouw JE; Anderson GL; Prentice RL; LaCroix AZ; Chlebowski RT; Howard BV; Thomson CA; Margolis KL; Lewis CE; Stefanick ML; Jackson RD; Johnson KC; Martin LW; Shumaker SA; Espeland MA; Wactawski-Wende J;
JAMA; 2017 Sep; 318(10):927-938. PubMed ID: 28898378
[TBL] [Abstract][Full Text] [Related]
9. Menopausal hormone therapy and risks of melanoma and nonmelanoma skin cancers: women's health initiative randomized trials.
Tang JY; Spaunhurst KM; Chlebowski RT; Wactawski-Wende J; Keiser E; Thomas F; Anderson ML; Zeitouni NC; Larson JC; Stefanick ML
J Natl Cancer Inst; 2011 Oct; 103(19):1469-75. PubMed ID: 21878677
[TBL] [Abstract][Full Text] [Related]
10. Postmenopausal hormone use and the risk of nephrolithiasis: results from the Women's Health Initiative hormone therapy trials.
Maalouf NM; Sato AH; Welch BJ; Howard BV; Cochrane BB; Sakhaee K; Robbins JA
Arch Intern Med; 2010 Oct; 170(18):1678-85. PubMed ID: 20937929
[TBL] [Abstract][Full Text] [Related]
11. Effect of estrogen therapy on gallbladder disease.
Cirillo DJ; Wallace RB; Rodabough RJ; Greenland P; LaCroix AZ; Limacher MC; Larson JC
JAMA; 2005 Jan; 293(3):330-9. PubMed ID: 15657326
[TBL] [Abstract][Full Text] [Related]
12. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study.
Espeland MA; Rapp SR; Shumaker SA; Brunner R; Manson JE; Sherwin BB; Hsia J; Margolis KL; Hogan PE; Wallace R; Dailey M; Freeman R; Hays J;
JAMA; 2004 Jun; 291(24):2959-68. PubMed ID: 15213207
[TBL] [Abstract][Full Text] [Related]
13. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin.
Heiss G; Wallace R; Anderson GL; Aragaki A; Beresford SA; Brzyski R; Chlebowski RT; Gass M; LaCroix A; Manson JE; Prentice RL; Rossouw J; Stefanick ML;
JAMA; 2008 Mar; 299(9):1036-45. PubMed ID: 18319414
[TBL] [Abstract][Full Text] [Related]
14. Breast tenderness and breast cancer risk in the estrogen plus progestin and estrogen-alone women's health initiative clinical trials.
Crandall CJ; Aragaki AK; Cauley JA; McTiernan A; Manson JE; Anderson G; Chlebowski RT
Breast Cancer Res Treat; 2012 Feb; 132(1):275-85. PubMed ID: 22042371
[TBL] [Abstract][Full Text] [Related]
15. Effects of menopausal hormone therapy on ductal carcinoma in situ of the breast.
Luo J; Cochrane BB; Wactawski-Wende J; Hunt JR; Ockene JK; Margolis KL
Breast Cancer Res Treat; 2013 Feb; 137(3):915-25. PubMed ID: 23315265
[TBL] [Abstract][Full Text] [Related]
16. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators.
Greendale GA; Reboussin BA; Sie A; Singh HR; Olson LK; Gatewood O; Bassett LW; Wasilauskas C; Bush T; Barrett-Connor E
Ann Intern Med; 1999 Feb; 130(4 Pt 1):262-9. PubMed ID: 10068383
[TBL] [Abstract][Full Text] [Related]
17. Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial.
Chlebowski RT; Anderson GL; Sarto GE; Haque R; Runowicz CD; Aragaki AK; Thomson CA; Howard BV; Wactawski-Wende J; Chen C; Rohan TE; Simon MS; Reed SD; Manson JE
J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26668177
[TBL] [Abstract][Full Text] [Related]
18. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women's Health Initiative results.
Kuhl H; Stevenson J
Gynecol Endocrinol; 2006 Jun; 22(6):303-17. PubMed ID: 16785155
[TBL] [Abstract][Full Text] [Related]
19. Menopausal Hormone Therapy and Risks of First Hospitalized Heart Failure and its Subtypes During the Intervention and Extended Postintervention Follow-up of the Women's Health Initiative Randomized Trials.
Liu L; Klein L; Eaton C; Panjrath G; Martin LW; Chae CU; Greenland P; Lloyd-Jones DM; Wactawski-Wende J; Manson JE
J Card Fail; 2020 Jan; 26(1):2-12. PubMed ID: 31536806
[TBL] [Abstract][Full Text] [Related]
20. Menopausal hormone therapy and the incidence of carpal tunnel syndrome in postmenopausal women: Findings from the Women's Health Initiative.
Al-Rousan T; Sparks JA; Pettinger M; Chlebowski R; Manson JE; Kauntiz AM; Wallace R
PLoS One; 2018; 13(12):e0207509. PubMed ID: 30513095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
